No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MIRM240517C35000
- 1.19
- 0.000.00%
15min DelayClose Mar 14 14:08 ET
0.00High0.00Low
0.00Open1.19Pre Close0 Volume0 Open Interest35.00Strike Price0.00Turnover5226.84%IV38.02%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry1.19Time Value100Contract SizeAmericanOptions Type0.2437Delta0.0314Gamma22.03Leverage Ratio-68.3818Theta0.0000Rho5.37Eff Leverage0.0006Vega
Intraday
- 5D
- 1D
News
Reported Saturday, Mirum Pharmaceuticals' LIVMARLI Data Presented At ESPGHAN, Featuring Key Findings On ALGS And PFIC
Presented by Professor Richard J. Thompson, MD, King's College London, United KingdomPatients with PFIC showed significant and sustained improvements in pruritus severity, serum bile acid (sBA) levels
Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting
- Seven abstracts highlighting ALGS and PFIC data, including three oral presentations - Long-term extension data from Phase 3 MARCH-ON PFIC study presented at plenary session and selected among the highest scoring
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase
Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss
Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley
Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley
Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Lowers Price Target to $53
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals with a Overweight and lowers the price target from $57 to $53.
Comments
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
5
1
Last week’s PDUFAs:
$BeiGene(BGNE.US$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb(BMY.US$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals(VNDA.US$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia(EYEN.US$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...
$BeiGene(BGNE.US$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb(BMY.US$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals(VNDA.US$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia(EYEN.US$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...
20
2
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Eyenovia(EYEN.US$ $Vanda Pharmaceuticals(VNDA.US$ $Mirum Pharmaceuticals(MIRM.US$ $Madrigal Pharmaceuticals(MDGL.US$ $Geron(GERN.US$ $Bristol-Myers Squibb(BMY.US$ $2seventy bio(TSVT.US$ $Legend Biotech(LEGN.US$ $OptiNose(OPTN.US$ $Orchard Therapeutics(ORTX.US$ $Merck & Co(MRK.US$ $Akebia Therapeutics(AKBA.US$ $AstraZeneca(AZN.US$ $Liquidia(LQDA.US$ $Esperion Therapeutics(ESPR.US$ $Regeneron Pharmaceuticals(REGN.US$ $BeiGene(BGNE.US$
$Eyenovia(EYEN.US$ $Vanda Pharmaceuticals(VNDA.US$ $Mirum Pharmaceuticals(MIRM.US$ $Madrigal Pharmaceuticals(MDGL.US$ $Geron(GERN.US$ $Bristol-Myers Squibb(BMY.US$ $2seventy bio(TSVT.US$ $Legend Biotech(LEGN.US$ $OptiNose(OPTN.US$ $Orchard Therapeutics(ORTX.US$ $Merck & Co(MRK.US$ $Akebia Therapeutics(AKBA.US$ $AstraZeneca(AZN.US$ $Liquidia(LQDA.US$ $Esperion Therapeutics(ESPR.US$ $Regeneron Pharmaceuticals(REGN.US$ $BeiGene(BGNE.US$
21
A huge 3 day span will see 7 companies in front of the review board:
$Mirum Pharmaceuticals(MIRM.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Geron(GERN.US$
$Bristol-Myers Squibb(BMY.US$
$Legend Biotech(LEGN.US$
$2seventy bio(TSVT.US$
$OptiNose(OPTN.US$
$Mirum Pharmaceuticals(MIRM.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Geron(GERN.US$
$Bristol-Myers Squibb(BMY.US$
$Legend Biotech(LEGN.US$
$2seventy bio(TSVT.US$
$OptiNose(OPTN.US$
5
4
Multiple insider sales at Mirum Pharmaceuticals raises potential investor concern, despite insider purchase by CFO displaying some confidence in the firm's future. Notably, insider ownership indicates alignment between management and smaller shareholders.
Read more
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long